2023

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Press Release: Availability of the Q4 2023 Memorandum for modelling purposes

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

Press Release: Sanofi’s Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Press Release: Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E. coli (ExPEC)

Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results

Press Release: Sanofi Enters Next Chapter of Play to Win Strategy

Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

Press Release: Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England Journal of Medicine

Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis

Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease

Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs

Media Update: Sanofi completes acquisition of Qunol®

Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review

Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A

Press Release: Availability of the Q3 2023 Memorandum for modelling purposes

Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change

Media Update: New data at ERS showed Xenpozyme® (olipudase alfa) improved respiratory functions in adults with ASMD

Media Update: New data at ERS showcases Sanofi's scientific leadership in addressing unmet needs across a variety of respiratory conditions 

Press Release: Sanofi announces changes to its Executive Committee

Press Release: Sanofi, Meningitis Research Foundation, and the Confederation of Meningitis Organisations ignite a global awareness initiative against meningitis with launch of The Meningitis Flag

Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease

Press release: Online availability of Sanofi’s half-year financial report for 2023

Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment

Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised

FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease

Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease

Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody

Press Release: ALTUVIIIO® late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing

Press Release: Availability of the Q2 2023 Memorandum for modelling purposes

Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim

Press Release: Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care

Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients

Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants

Media Update: New data from Sanofi’s diverse, differentiated oncology pipeline and portfolio to be presented at ASCO 2023

Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan

Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

Media Update: Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine

Press Release: New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline

Press Release: Sanofi completes acquisition of Provention Bio, Inc.

Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

Press Release: Elisabeth Moreno to join Sanofi's Diversity, Equity and Inclusion Board

Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

Press Release: Availability of the Q1 2023 Memorandum for modelling purposes

Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A

Press Release: FDA approves once-weekly ALTUVIIIOTM, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection. This positive event triggers impairment reversal, impacting 2022 IFRS net income; no change on business net income (non-IFRS)

Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

Media Update: New data for tolebrutinib, Sanofi’s investigational brain- penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression

Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Media Update: Pediatric research at ReSViNET 2023 underscores Beyfortus’ potential to prevent RSV disease in infants

Press Release: Sanofi announces change in R&D leadership

Press Release: Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone

Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis

Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A

Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M

Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants

Press Release: Availability of the Q4 2022 Memorandum for modelling purposes